**AUB KQ1 Evidence Table (Reference ID #1777)**

| **Study Description** | **Intervention(s)/ Comparator(s)** | **Patient Population** | **Baseline Measure(s)** | **Outcome Measure(s)** | **Overall Quality**  **Risk of Bias** |
| --- | --- | --- | --- | --- | --- |
| **Author:**  Oner and Muderris, 2011  **Country:**  Turkey  **Enrollment period:**  March 2008 to April 2009  **Intervention setting:**  University gynecologic endocrinology clinic  **Funding:**  NR  **Author industry relationship disclosures:**  NR  **Study Design:**  RCT  **Blinding:**  NR | **Intervention:**  1.5 g/day metformin (500 mg 3 times per day)  **Comparator:**  1.8 g/day N-acetyl-cysteine (600 mg 3 times per day)  **Groups:**  **G1:** Metformin  **G2:** N-acetyl-cysteine  **Followup:**  24 weeks | **Inclusion criteria:**  PCOSa with hirsutism and menstrual irregularity  **Exclusion criteria:**  Congenital adrenal hyperplasia, Cushing’s syndrome or androgen secreting tumors, thyroid disease, hyperprolactinemia  Diabetes mellitus or impaired glucose tolerance  Use of drugs known to affect carbohydrate metabolism within 3 months preceding the study  **N at enrollment:**  **G1:** 50  **G2:** 50  **N at followup:**  **G1:** 30  **G2:** 45  **Age, mean years ± SD:**  **G1:** 22.6 ± 4.8  **G2:** 23.7 ± 4.4  **BMI, mean kg/m2 ± SD:**  **G1:** 24.3 ± 6.2  **G2:** 23.0 ± 4.6  **Parity:**  NR  **Race/ethnicity:**  NR | **Menstrual cycle:**  Regular, n (%):  **G1:** 5 (17)  **G2:** 13 (29)  **G1 vs. G2:** p=NS  Irregular, n (%):  **G1:** 25 (83)  **G2:** 32 (71)  **G1 vs. G2:** p=NS | **Menstrual cycle:**  Regular, n (%):  **G1:** 14 (47)  **G2:** 24 (53)  **G1 vs. G2:** p=NS  Irregular, n (%):  **G1:** 16 (53)  **G2:** 21 (47)  **G1 vs. G2:** p=NS  Restoration of menstrual regularity, n (%):  **G1:** 9 (36)  **G2:** 11 (34)  **G1 vs. G2:** p=NS  **Quality of life:**  NR  **Pain:**  NR  **Sexual function:**  NR  **Patient satisfaction:**  NR  **Fertility:**  NR  **Time to conception:**  NR  **Additional interventions:**  NR  **Adverse Events:**  Discontinued due to gastrointestinal side effects, n (%):  **G1:** 2 (4)  **G2:** NR | **Overall quality:**  Poor  **Risk of bias:**  Randomization:  Unclear  Allocation concealment:  Unclear  Selective reporting:  Low  Blinding patients/personnel:  Unclear  Blinding outcome assessment:  Unclear  Incomplete outcome reporting:  High  Other:  Unclear |

**Table Notes:** a PCOS defined as presence of at least two of following three criteria: (1) oligo- or anovulation, (2) clinical and/or chemical signs of hyperandrogenism and/or (3) polycystic ovaries.